QUATTRO-II: A multicenter randomized trial comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Efficacy and safety analysis

被引：0

作者：

Kotaka, M. ^{[1
]}

Bando, H. ^{[2
]}

Satake, H. ^{[3
]}

Kotani, D. ^{[4
]}

Hamaguchi, T. ^{[5
]}

Shiozawa, M. ^{[6
]}

Ikumoto, T. ^{[1
]}

Masuishi, T. ^{[7
]}

Yasui, H. ^{[8
]}

Kagawa, Y. ^{[9
]}

Oki, E. ^{[10
]}

Yamamoto, Y. ^{[11
]}

Kawakami, H. ^{[12
]}

Boku, S. ^{[13
]}

Komatsu, Y. ^{[14
]}

Taniguchi, H. ^{[7
]}

Muro, K. ^{[15
]}

Yamazaki, K. ^{[16
]}

Misumi, T. ^{[17
]}

Yoshino, T. ^{[4
]}

Kato, T. ^{[18
]}

Tsuji, A. ^{[16
]}

机构：

[1] Sano Hosp, Gastrointestinal Canc Ctr, Kobe, Japan

[2] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan

[3] Kochi Med Sch, Dept Med Oncol, Nankoku, Japan

[4] Natl Canc Ctr Hosp East, Kashiwa, Japan

[5] Saitama Med Univ, Int Med Ctr, Hidaka, Japan

[6] Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Yokohama, Japan

[7] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Japan

[8] Kobe City Med Ctr Gen Hosp, Dept Med Oncol, Kobe, Japan

[9] Osaka Gen Med Ctr, Dept Gastroenterol Surg, Osaka, Japan

[10] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan

[11] Univ Tsukuba, Dept Gastroenterol, Fac Med, Tsukuba, Japan

[12] Kindai Univ, Fac Med, Osakasayama, Japan

[13] Kansai Med Univ, Hirakata, Japan

[14] Hokkaido Univ Hosp, Div Canc Ctr, Sapporo, Japan

[15] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan

[16] Shizuoka Canc Ctr, Dept Gastrointestinal Oncol, Shizuoka, Japan

[17] Natl Canc Ctr Hosp East, Dept Data Sci, Kashiwa, Japan

[18] Osaka Natl Hosp, Natl Hosp Org, Dept Surg, Osaka, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.04.205

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-149

引用

页码：S68 / S68

页数：1

共 50 条

[1] A multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab and FOLFOXIRI plus bevacizumab as the first-line treatment for metastatic colorectal cancer: A safety analysis of the QUATTRO-II study
Masuishi, T.
Bando, H.
Satake, H.
Kotani, D.
Hamaguchi, T.
Shiozawa, M.
Ikumoto, T.
Kagawa, Y.
Yasui, H.
Moriwaki, T.
Kawakami, H.
Boku, S.
Oki, E.
Komatsu, Y.
Taniguchi, H.
Muro, K.
Kotaka, M.
Yamazaki, K.
Misumi, T.
Yoshino, T.
Kato, T.
Tsuji, A.
ANNALS OF ONCOLOGY, 2022, 33 : S276 - S277
[2] Quattro-II study: A multicenter randomized phase II study comparing capoxiri plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment
Tsuji, Akihito
Yoshino, Takayuki
Yamanaka, Takeharu
Bando, Hideaki
Satake, Hironaga
Yamazaki, Kentaro
Taniguchi, Hiroya
Oki, Eiji
Kotaka, Masahito
Oba, Koji
Miyata, Yoshinori
Muro, Kei
Komatsu, Yoshito
Baba, Hideo
Kato, Takeshi
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[3] A multicenter randomized phase II trial comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study
Bando, Hideaki
Satake, Hironaga
Kotani, Daisuke
Hamaguchi, Tetsuya
Shiozawa, Manabu
Ikumoto, Taro
Okita, Yoshihiro
Masuishi, Toshiki
Kagawa, Yoshinori
Yasui, Hisateru
Oki, Eiji
Komatsu, Yoshito
Taniguchi, Hiroya
Muro, Kei
Kotaka, Masahito
Yamazaki, Kentaro
Misumi, Toshihiro
Yoshino, Takayuki
Kato, Takeshi
Tsuji, Akihito
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[4] Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer
Miyo, Masaaki
Kato, Takeshi
Yoshino, Takayuki
Yamanaka, Takeharu
Bando, Hideaki
Satake, Hironaga
Yamazaki, Kentaro
Taniguchi, Hiroya
Oki, Eiji
Kotaka, Masahito
Oba, Koji
Miyata, Yoshinori
Muro, Kei
Komatsu, Yoshito
Baba, Hideo
Tsuji, Akihito
BMC CANCER, 2020, 20 (01)
[5] Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer
Masaaki Miyo
Takeshi Kato
Takayuki Yoshino
Takeharu Yamanaka
Hideaki Bando
Hironaga Satake
Kentaro Yamazaki
Hiroya Taniguchi
Eiji Oki
Masahito Kotaka
Koji Oba
Yoshinori Miyata
Kei Muro
Yoshito Komatsu
Hideo Baba
Akihito Tsuji
BMC Cancer, 20
[6] QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC
Bando, Hideaki
Kotani, Daisuke
Satake, Hironaga
Hamaguchi, Tetsuya
Shiozawa, Manabu
Kotaka, Masahito
Masuishi, Toshiki
Yasui, Hisateru
Kagawa, Yoshinori
Komatsu, Yoshito
Oki, Eiji
Yamamoto, Yoshiyuki
Kawakami, Hisato
Misumi, Toshihiro
Taniguchi, Hiroya
Yamazaki, Kentaro
Muro, Kei
Yoshino, Takayuki
Kato, Takeshi
Tsuji, Akihito
MED, 2024, 5 (09):
[7] A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study
Oki, Eiji
Kato, Takeshi
Bando, Hideaki
Yoshino, Takayuki
Muro, Kei
Taniguchi, Hiroya
Kagawa, Yoshinori
Yamazaki, Kentaro
Yamaguchi, Tatsuro
Tsuji, Akihito
Iwamoto, Shigeyoshi
Nakayama, Goro
Emi, Yasunori
Touyama, Tetsuo
Nakamura, Masato
Kotaka, Masahito
Sakisaka, Hideki
Yamanaka, Takeharu
Kanazawa, Akiyoshi
CLINICAL COLORECTAL CANCER, 2018, 17 (02) : 147 - 155
[8] FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF BRAF MUTANT METASTATIC COLORECTAL CANCER PATIENTS
Salvatore, Lisa
Loupakis, Fotios
Cremolini, Chiara
Schirripa, Marta
Masi, Gianluca
Antoniotti, Carlotta
Fornaro, Lorenzo
Sensi, Elisa
Lupi, Cristiana
Bergamo, Francesca
Lonardi, Sara
Zagonel, Vittorina
Fontanini, Gabriella
Falcone, Alfredo
ANNALS OF ONCOLOGY, 2012, 23 : 93 - 93
[9] FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
Loupakis, F.
Cremolini, C.
Salvatore, L.
Masi, G.
Sensi, E.
Schirripa, M.
Michelucci, A.
Pfanner, E.
Brunetti, I.
Lupi, C.
Antoniotti, C.
Bergamo, F.
Lonardi, S.
Zagonel, V.
Simi, P.
Fontanini, G.
Falcone, A.
EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 57 - 63
[10] Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial
Cremolini, Chiara
Malmorino, Federica
Bergamo, Francesca
Aprile, Giuseppe
Salvatore, Lisa
Masi, Gianluca
Dell'Aquila, Emanuela
Antoniotti, Carlotta
Murgioni, Sabina
Allegrini, Giacomo
Borelli, Beatrice
Gemma, Donatello
Casagrande, Mariaelena
Granetto, Cristina
Delfanti, Sara
Di Donato, Samantha
Schirripa, Marta
Sensi, Elisa
Tonini, Giuseppe
Lonardi, Sara
Fontanini, Gabriella
Boni, Luca
Falcone, Alfredo
EUROPEAN JOURNAL OF CANCER, 2019, 109 : 175 - 182

← 1 2 3 4 5 →